Redwire (RDW) announced that it has been awarded a contract from Aspera Biomedicines to conduct space-based research and analysis on a new cancer treatment using Redwire’s Pharmaceutical In-space Laboratory technology.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDW:
- Redwire awarded contract by SpaceTech to provide avionics technology
- Redwire Holds 2025 Annual Shareholders Meeting
- Redwire price target lowered to $20 from $30 at Roth Capital
- 3 Best Stocks to Buy Now, 5/13/2025, According to Top Analysts
- Redwire Corporation: Buy Rating Affirmed Amid Growth Prospects and Strategic Acquisitions